Barclays analyst Steven Valiquette maintained a Hold rating on Henry Schein (HSIC) on May 7 and set a price target of $64. The company’s shares opened today at $67.93, close to its 52-week high of $71.61.
According to TipRanks.com, Valiquette is a 4-star analyst with an average return of 4.8% and a 48.3% success rate. Valiquette covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Walgreens Boots Alliance, and Patterson Companies Inc.
Currently, the analyst consensus on Henry Schein is a Moderate Buy with an average price target of $67.57, representing a -0.5% downside. In a report issued on May 2, Cleveland Research also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $71.61 and a one-year low of $45.82. Currently, Henry Schein has an average volume of 1.92M.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments.
